SEC 13F Intelligence

Artal Group S.A. / KYMR

Artal Group S.A.’s Kymera Therapeutics Inc Position

Does Artal Group S.A. own Kymera Therapeutics Inc (KYMR)? Not currently — the last reported position was 3.01M shares worth $90M in Q2 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$90M
Q2 2024
Shares
3.01M
% of Portfolio
+2.29%
Quarters Held
16
position exited

Position History KYMR

Reported value by quarter
Q3 ’20: $8MQ3 ’20Q4 ’20: $16MQ1 ’21: $10MQ1 ’21Q2 ’21: $12MQ3 ’21: $23MQ3 ’21Q4 ’21: $63MQ1 ’22: $42MQ1 ’22Q2 ’22: $20MQ3 ’22: $33MQ3 ’22Q4 ’22: $49,920Q1 ’23: $53,492Q1 ’23Q2 ’23: $41,505Q3 ’23: $25,094Q3 ’23Q4 ’23: $64,433Q1 ’24: $122MQ1 ’24Q2 ’24: $90Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q2 20243.01M$90M+2.29%
Q1 20243.03M$122M+3.10%
Q4 20232.53M$64,433+2.14%
Q3 20231.81M$25,094+1.08%
Q2 20231.81M$41,505+1.29%
Q1 20231.81M$53,492+3.18%
Q4 20222.00M$49,920+2.79%
Q3 20221.50M$33M+1.39%
Q2 20221.00M$20M+1.05%
Q1 20221.00M$42M+1.77%
Q4 20211.00M$63M+1.72%
Q3 2021400.0K$23M+0.53%
Q2 2021250.0K$12M+0.25%
Q1 2021250.0K$10M+0.17%
Q4 2020250.0K$16M+0.33%
Q3 2020250.0K$8M+0.20%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Artal Group S.A.’s full portfolio or all institutional holders of KYMR.